Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | FLAG-IDA and ponatinib in blast phase CML: MATCHPOINT trial

Mhairi Copland • 7 Dec 2019
ASH 2019
Chronic Myeloid Leukemia Leukemia Cytarabine Fludarabine G-CSF Idarubicin Ponatinib
MATCHPOINT

Mhairi Copland, PhD, MBChB, FRCP, FRCPath, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, discusses the results from the MATCHPOINT phase I/II trial. This study was designed to find a safe and effective dose of ponatinib when used in combination with FLAG-IDA chemotherapy (fludarabine, cytarabine, idarubicin and G-CSF) in patients with chronic myeloid leukemia (CML) whose disease has moved in to blast phase. Results confirm that FLAG-IDA plus ponatinib is a tolerable combination and represents a potentially important advance in the treatment of blast phase CML, a rare complication which currently has a very poor outcome. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Mhairi Copland

3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
1:36
The importance of improving treatment-free remission in patients with CML
Mhairi Copland • 29 Sep 2022
1:12
The challenges associated with long-term TKI use in patients with CML
Mhairi Copland • 29 Sep 2022
2:29
Treatment options for patients with CML
Mhairi Copland • 29 Sep 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals